Tags: flu | drug | roche

New Flu Drug Speeds Relief for At-Risk Patients, Roche Says

New Flu Drug Speeds Relief for At-Risk Patients, Roche Says
(Dreamstime)

Thursday, 04 October 2018 04:28 AM

A new flu drug that speeds relief from serious complications for at-risk patients is in the pipeline for FDA approval in December, Swiss drugmaker Roche said on Thursday.

Roche said baloxavir marboxil significantly sped time to relief for patients highly vulnerable to flu symptoms, a late-stage clinical trial has shown.

If approved, it would mark the first new way to treat influenza in nearly two decades, Roche added.

The CAPSTONE-2 phase III trial showed the median time for improvement of symptoms versus placebo dropped to 73.2 hours from 102.3 hours for at-risk patients including people aged 65 or older and those with asthma, chronic lung disease, morbid obesity, or heart disease.

The single-dose oral medicine — discovered and developed by Shionogi & Co Ltd and sold in Japan as Xofluza — is the first to show such benefits, Roche said in a statement.

The drug was well-tolerated and the trial threw up no new safety signals.

"This study adds to the growing body of evidence supporting baloxavir marboxil as a potential first-in-class antiviral flu treatment, and we plan to discuss these data with health authorities around the world," Roche Chief Medical Officer Sandra Horning said.

The U.S. Food and Drug Administration has granted priority review for the drug in people aged 12 and older based on results from earlier studies, Roche said. It is set to decide by Dec. 24 whether to approve it.

© 2018 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
A new flu drug that speeds relief from serious complication for at-risk ratients is in the pipeline for FDA approval in December, Swiss drugmaker Roche said on Thursday.
flu, drug, roche
232
2018-28-04
Thursday, 04 October 2018 04:28 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved